Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Micurx Pharmaceuticals / Equity Capital Markets

<p>MicuRx Pharma is the fourth biotech company to file with Hong Kong Stock Exchange for a listing under the new rule. In this insight, we will look at the following topics:</p>
<ul>
<li>Two antibiotic products in the pipeline. The target treatment and progress of clinical trials.</li>
<li>The multidrug-resistant (MDR) market.</li>
<li>The issue with the antibiotic market.</li>
<li>The company's investors and shareholders.</li>
</ul>
<p>We will discuss the company's valuation in our next insight.</p>

MicuRx Pharma is the fourth biotech company to file with Hong Kong Stock Exchange for a listing under the new rule. In this insight, we will look at the following topics:

Two antibiotic products in the pipeline. The target treatment and progress of clinical trials.
The multidrug-resistant (MDR) market.
The issue with the antibiotic market.
The company's investors and shareholders.

We will discuss the company's valuation in our next insight.

MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment

China

Micurx Pharmaceuticals Inc. discovers and develops novel antibiotics to combat drug-resistant bacterial infections. The Company offers a pipeline of discovery and development programs for the treatment of Gram-positive bacteria, Gram-negative bacteria and fungal infections. Micurx Pharmaceuticals operates and markets to customers in the United States and China.

Micurx Pharmaceuticals (0276457D US)

MicuRx Pharma (盟科医药) IPO: Betting on Single Drug in the Not so Attractive Antibiotic Segment

MicuRx Pharma is the fourth biotech company to file with Hong Kong Stock Exchange for a listing under the new rule. In this insight, we will look...

Ke Yan, CFA, FRM